Chemopreventive Drug Development: Perspectives and Progress

Cancer Epidemiology Biomarkers and Prevention

Volumn 3, Issue 1, 1994, Pages 85-98

  Kelloff, Gary J ^a   Boone, Charles W ^a   Crowell, James A ^a   Steele, Vernon E ^a   Lubet, Ronald ^a   Sigman, Caroline C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates ^*  (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANDROGEN; ANTIOXIDANT; BETA CAROTENE; CALCIUM; CARBENOXOLONE; CURCUMIN; EFLORNITHINE; ELLAGIC ACID; FENRETINIDE; FINASTERIDE; FLUASTERONE; FUMARIC ACID; GLYCYRRHETINIC ACID; IBUPROFEN; ISOTHIOCYANIC ACID DERIVATIVE; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; PHENHEXYL ISOTHIOCYANATE; PIROXICAM; PRASTERONE; RETINOID; RETINOL; S ALLYLCYSTEINE; SULINDAC; TAMOXIFEN; UNCLASSIFIED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOMA IN SITU; CLINICAL TRIAL; COLON CANCER; DRUG MECHANISM; DYSPLASIA; EDEMA; HUMAN; HYPERTENSION; HYPOKALEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPLAKIA; LUNG CANCER; MOUTH CANCER; NONHUMAN; ORAL DRUG ADMINISTRATION; PRECANCER; PRIORITY JOURNAL; REVIEW; SKIN CANCER; TRACHEA CANCER;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; FORECASTING; NEOPLASMS, EXPERIMENTAL; RESEARCH;

EID: 0028232269     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (226)

1. Boone, C. W., Kelloff, G. J., and Malone, W. F. Identification of candidate chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res., 50: 2–9, 1990.
2. Kelloff, G. J., Malone, W. F., Boone, C. W., Sigman, C. C., and Fay, J. R. Progress in applied chemoprevention research. Semin. Oncol., 17: 438–455, 1990.
3. Kelloff, G. J., Boone, C. W., Malone, W. F., and Steele, V. E. Recent results in preclinical and clinical drug development of chemopreventive agents at the National Cancer Institute. In. L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 41–56. Boca Raton: CRC Press, 1992.
4. Anderson, M. C. Premalignant and malignant diseases of the cervix. In: H. Fox (ed.), Haines and Taylor Obstetric and Gynecological Pathology, pp. 225–277. New York: Churchill Livingston, 1987.
5. Boone, C. W., Kelloff, G. J., and Steele, V. E. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res., 52: 1651–1659, 1992.
6. Wattenberg, L. W. Chemoprevention of cancer. Cancer Res., 45: 1–8, 1985.
7. Wattenberg, L. W. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res. (Suppl.), 52: 2085s–2091s, 1992.
8. Talalay, P. The role of enzyme induction in protection against carcinogenesis. In: L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 469–478. Boca Raton: CRC Press, 1992.
9. Breimer, L. H. Molecular mechanisms of oxygen radical carcinogenesis and mutagenesis: the role of DNA base damage. Mol. Carcinogen, 3: 188–197, 1990.
10. Kensler, T. W., and Taffe, B. G. Free radicals in tumor promotion. Free Rad. Biol. Med., 2: 347, 1986.
11. Reddy, B. S., Nayini, J., Tokumo, K., Rigotty, J., Zang, E., and Kelloff, G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D, L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res., 50: 2562–2568, 1990.
12. Rao, C. V., Tokumo, K., Rigotty, J., Zang, E., Kelloff, G., and Reddy, B. S. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α-difluoromethylornithine, 16-α-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res., 51: 4528–4534, 1991.
13. Ratko, T. A., Detrisac, C. J., Dinger, N. M., Thomas, C. F., Kelloff, G. J., and Moon, R. C. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res., 49: 4472–4476, 1989.
14. Moon, R. C., Kelloff, G. J., Detrisac, C. J., Steele, V. E., Thomas, C. F., and Sigman, C. C. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res., 12: 1147–1154, 1992.
15. Moon, R. C., McCormick, D. L., and Mehta, R. G. Inhibition of carcinogenesis by retinoids. Cancer Res. (Suppl.), 43: 2469s–2475s, 1983.
16. Moon, R. C., and Mehta, R. G. Chemoprevention of experimental carcinogenesis in animals. Prev. Med., 18: 576–591, 1989.
17. Willett, W. C., Polk, B. F., Underwood, B. A., Stampfer, M. J., Pressel, S., Rosner, B., Taylor, J. O., Schneider, K., and Hames, C. G. Relation of serum vitamins A and E and carotenoids to the risk of cancer. N. Engl. J. Med., 310: 430–434, 1984.
18. Wald, N. J., Boreham, J., Hayward, J. L., and Bulbrook, R. D. Plasma retinol, β-carotene and vitamin E levels in relation to the future risk of breast cancer. Br. J. Cancer, 49: 321–324, 1984.
19. Nomura, A. M. Y., Stemmermann, G. N., Heilbrun, L. K., Salkeld, R. M., and Vuilleumier, J. P. Serum vitamin levels and the risk of cancer of specific sites in men of Japanese ancestry in Hawaii. Cancer Res., 45: 2369–2372, 1985.
20. Salonen, J. T., Salonen, R., Lappetelainen, R., Maenpaa, P. H., Alfthan, G., and Puska, P. Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case-control analysis of prospective data. Br. Med. J., 290: 417–420, 1985.
21. Menkes, M. S., Comstock, G. W., Vuillemier, J. P., Helsing, K. J., Rider, A., and Brookmeyer, R. Serum β-carotene, vitamins A and E, selenium, and the risk of lung cancer. N. Engl. J. Med., 315: 1250–1254, 1986.
22. Helzlsouer, K. J., Comstock, G. W., and Morris, J. S. Selenium, lycopene, α-tocopherol, β-carotene, retinol, and subsequent bladder cancer. Cancer Res., 49: 6144–6148, 1989.
23. Hill, D. L., and Grubbs, C. J. Retinoids and cancer prevention. Annu. Rev. Nutr., 72: 161–181, 1992.
24. Costa, A., Veronesi, U., De Palo, G., Chiesa, F., Formelli, F., Marubini, E., Del Vecchio, M., and Nava, M. Chemoprevention of cancer with the synthetic retinoid fenretinide: clinical trials in progress at the Milan Cancer Institute. In: L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 95–112. Boca Raton: CRC Press, 1992.
25. Bjelke, E. Dietary vitamin A and human lung cancer. Int. J. Cancer, 15: 561–565, 1975.
26. MacLennan, R., Da Costa, J., Day, N. E., Law, C. H., Ng, Y. K., and Shanmugaratnam, K. Risk factors for lung cancer in Singapore Chinese, a population with high female incidence rates. Int. J. Cancer, 20: 854–860, 1977.
27. Hirayama, T. Diet and cancer. Nutr. Cancer, 7: 67–81, 1979.
28. Peto, R., Doll, R., Buckley, J. D., and Sporn, M. B. Can dietary β-carotene materially reduce human cancer rates? Nature (Lond.), 290: 201–208, 1981.
29. Shekelle, R. B., Liu, S., Raynor, W. J., Lepper, M., Maliza, C., Rossof, A. H., Paul, O., Shryock, A. M., and Stamler, J. Dietary vitamin A and risk of cancer in the Western Electric Study. Lancet, 2: 1185–1189, 1981.
30. Kvale, G., Bjelke, E., and Gart, J. J. Dietary habits and lung cancer risk. Int. J. Cancer, 31: 397–405, 1983.
31. Kolonel, L. N., Hinds, M. W., Nomura, A. M. Y., Hankin, J. H., and Lee, J. Relationship of dietary vitamin A and ascorbic acid intake to the risk for cancers of the lung, bladder, and prostate in Hawaii. NCI Monogr., 69: 137–142, 1985.
32. Bond, G. G., Thompson, F. E., and Cook, R. R. Dietary vitamin A and lung cancer: results of a case-control study among chemical workers. Nutr. Cancer, 9: 109–121, 1987.
33. Fontham, E. T., Pickle, L. W., Haenszel, W., Correa, P., Lin, Y. P., and Falk, R. T. Dietary vitamins A and C and lung cancer risk in Louisiana. Cancer (Phila.), 62: 2267–2273, 1988.
34. Greenberg, E. R., Baron, J. A., Stukel, T. A., Stevens, M. M., Mandel, J. S., Spencer, S. K., Elias, P. M., Lowe, N., Nierenberg, D. W., Bayrd, G., Vance, J. C., Freeman, D. H., Jr., Clendenning, W. E., Kwan, T., and the Skin Cancer Prevention Study Group. A clinical trial of β-carotene to prevent basal-cell and squamous-cell cancers of the skin. N. Engl. J. Med., 323: 789–795, 1990.
35. Garewal, H. S., Meyskens, F. L., Jr., Killen, D., Reeves, D., Kiersch, T. A., Elletson, H., Strosberg, A., King, D., and Steinbronn, K. Response of oral leukoplakia to beta-carotene. J. Clin. Oncol., 8: 1715–1720, 1990.
36. Garewal, H. S., and Meyskens, F. L., Jr. Retinoids and carotenoids in the prevention of oral cancer: a critical appraisal. Cancer Epidemiol., Biomarkers & Prev., 7: 155–159, 1992.
37. Krinsky, N. I., Mathews-Roth, M. M., Welankiwar, S., Sehgal, P. K., Lausen, N. C. G., and Russett, M. The metabolism of [14C]β-carotene and the presence of other carotenoids in rats and monkeys. J. Nutr., 720: 81–87, 1990.
38. Moon, R. C., Rao, K. V. N., Detrisac, C. J., and Kelloff, G. J. Retinoid chemoprevention of lung cancer. In: L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 83–93. Boca Raton: CRC Press, 1992.
39. Omenn, G. S., Goodman, G., Grizzle, J., Thornquist, M., Rosenstock, L., Barnhart, S., Anderson, G., Balmes, J., Cherniack, M., Cone, J., Cullen, M., Glass, A., Keogh, J., Meyskens, F., and Valanis, B. CARET, the β-carotene and retinol efficacy trial to prevent lung cancer in asbestos-exposed workers and in smokers. Anti-Cancer Drugs, 2: 79–86, 1991.
40. Hong, W. K., Endicott, J., Itri, L. M., Doos, W., Batsakis, J. G., Bell, R., Fofonoff, S., Byers, R., Atkinson, E. N., Vaughan, C., Toth, B. B., Kramer, A., Dimery, I. W., Skipper, P., and Strong, S. 13-cis-retinoic acid in the treatment of oral leukoplakia. New Engl. J. Med., 315: 1501–1505, 1986.
41. Lippman, S. M., Toth, B. B., Batsakis, J. G., Lee, J. S., Weber, R. S., Craddock, C., Martin, J. W., Hays, G., Lotan, R., and Hong, W. K. Phase-III trial to maintain remission of oral premalignancy: Low-dose 13-cis retinoic acid versus β-carotene. Proc. Am. Soc. Clin. Oncol., 11: 243, 1992.
42. Hong, W. K., Lippmann, S. M., Itri, L., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kramer, A. M., Lotan, R., Peters, L. J., Dimery, I. W., Brown, W., and Goepfert, H. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 323: 795–800, 1990.
43. Benner, S. E., Hong, W. K., and Lippman, S. M. Treatment of field can-cerization. In: L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 113–125. Boca Raton: CRC Press, 1992.
44. Lipkin, M., and Newmark, H. Effect of dietary calcium on colonic epithelial-cell proliferation in subjects at high risk for familial colonic cancer. N. Engl. J. Med., 313: 1381–1384, 1985.
45. Buset, M., Lipkin, M., Winawer, S., Swaroop, S., and Friedman, E. Inhibition of human colonic epithelial cell proliferation in vivo and in vitro by calcium. Cancer Res., 46: 5426–5430, 1986.
46. Gregoire, R. C., Stern, H. S., Yeung, K. S., Stadler, J., Langley, S., Furrer, R., and Bruce, W. R. Effect of calcium supplementation on mucosal cell proliferation in high risk patients for colon cancer. Gut, 30: 376–382, 1989.
47. Wargovich, M. J., Eng, V. W. S., Newmark, H. L., and Bruce, W. R. Calcium ameliorates the toxic effect of deoxycholic acid on colonic epithelium. Carcinogenesis (Lond.), 4: 1205–1207, 1983.
48. Lipkin, M., Friedman, E., Winawer, S. J., and Newmark, H. Colonic epithelial cell proliferation in responders and nonresponders to supplemental dietary calcium. Cancer Res., 49: 248–254, 1989.
49. Pamukcu, A. M., Yalciner, S., and Bryan, G. T. Inhibition of carcinogenic effect of bracken fern Pteridium aquilinum by various chemicals. Cancer (Suppl.), 40: 2450–2454, 1977.
50. Appleton, G. V., Davies, P. W., Bristol, J. B., and Williamson, R. C. Inhibition of intestinal carcinogenesis by dietary supplementation with calcium. Br. J. Surg., 74: 523–525, 1987.
51. Wargovich, M. J., Stephens, L. C., and Gray, K. N. Effect of two human nutrient density levels of calcium on promotional phase of colon tumorigenesis in the F344 rat. Proc. Am. Assoc. Cancer Res., 30: 196, 1989.
52. Cuzick, J., and Baum, M. Tamoxifen and contralateral breast cancer. Lancet, 2: 282, 1986.
53. Jordan, V. C. Effect of tamoxifen (ICI 46474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer, 72: 419–424, 1976.
54. Welsch, C. W., Goodrich-Smith, M., Brown, C. K., Mackie, D., and Johnson, D. 2-bromo-α-ergocryptine (CB-154) and tamoxifen (ICI 46474) induced suppression of the genesis of mammary carcinomas in female rats treated with 7, 12-dimethylbenz(a)anthracene (DMBA): a comparison. Oncology, 39: 88–92, 1982.
55. Fisher, B. Experimental and clinical justification for the use of tamoxifen in a breast cancer prevention trial: a description of the NSABP effort. Proc. Am. Assoc. Cancer Res., 33: 567–568, 1992.
56. Stoner, E. The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J. Urol., 747: 1298–1302, 1992.
57. Boone, C. W., Steele, V. E., and Kelloff, G. J. Screening for chemopreventive (anticarcinogenic) compounds in rodents. Mutat. Res., 267: 251–255, 1992.
58. Pegg, A. E., and McCann, P. P. Polyamine metabolism and function. Am. J. Physiol., 243: C212–C221, 1982.
59. McCann, P. P., Pegg, A. E., and Sjoerdsma, A. Inhibition of Polyamine Metabolism: Biological Significance and Basis for New Therapies. New York: Academic Press, 1987.
60. Luk, G. D., and Casero, R. A. Polyamines in normal and cancer cells. Adv. Enzyme Regul., 26: 91–105, 1987.
61. Weeks, C. E., Herrmann, A. L., Nelson, F. R., and Slaga, T. J. α-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc. Natl. Acad. Sci. USA, 79: 6028–6032, 1982.
62. Rozhin, J., Wilson, P. S., Bull, A. W., and Nigro, N. D. Ornithine decarboxylase activity in the rat and human colon. Cancer Res., 44: 3226–3230, 1984.
63. Takigawa, M., Verma, A. K., Simsiman, R. C., and Boutwell, R. K. Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by α-difluoromethylornithine. Cancer Res., 43: 3732–3738, 1983.
64. Verma, A. K., Duvick, L., and Ali, M. Modulation of mouse skin tumor promotion by dietary 13-cis-retinoic acid and α-difluoromethylornithine. Carcinogenesis (Lond.), 7: 1019–1023, 1986.
65. Kingsnorth, A. N., King, W. W. K., Diekema, K. A., McCann, P. P., Ross, J. S., and Malt, R. A. Inhibition of ornithine decarboxylase with difluoromethylornithine: reduced incidence of dimethylhydrazine-induced colon tumors in mice. Cancer Res., 43: 2545–2549, 1983.
66. Nigro, N. D., Bull, A. W., and Boyd, M. E. Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J. Natl. Cancer Inst., 77: 1309–1313, 1986.
67. Homma, Y., Kakizoe, T., Samma, S., and Oyasu, R. Inhibition of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat urinary bladder carcinogenesis by α-difluoromethylornithine. Cancer Res., 47: 6176–6179, 1987.
68. Ratko, T. A., Detrisac, C. J., Rao, C. V., Thomas, C. F., Kelloff, G. J., and Moon, R. C. Interspecies analysis of the chemopreventive efficacy of dietary α-difluoromethylornithine. Anticancer Res., 70: 67–72, 1990.
69. Thompson, H. J., Herbst, E. J., Meeker, L. D., Minocha, R., Ronan, A. M., and Fite, R. Effect of D, L-α-difluoromethylornithine on murine mammary carcinogenesis. Carcinogenesis (Lond.), 5: 1649–1651, 1984.
70. Thompson, H. J., Meeker, L. D., Herbst, E. J., Ronan, A. M., and Minocha, R. Effect of concentration of D, L-2-difluoromethylornithine on murine mammary carcinogenesis. Cancer Res., 45: 1170–1173, 1985.
71. Thompson, H. J., Ronan, A. M., Ritacco, K. A., and Meeker, L. D. Effect of tamoxifen and D, L-2-difluoromethylornithine on the growth, ornithine decarboxylase activity and polyamine content of mammary carcinomas induced by 1-methyl-1-nitrosourea. Carcinogenesis (Lond.), 7: 837–840, 1986.
72. Thompson, H. J., and Ronan, A. M. Effect of D, L-2-difluoromethylornithine and endocrine manipulation on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis (Lond.), 7: 2003–2006, 1986.
73. Abeloff, M. D., Slavik, M., Luk, G. D., Griffin, C. A., Hermann, J., Blanc, O., Sjoerdsma, A., and Baylin, S. B. Phase I trial and pharmacokinetic studies of α-difluoromethylornithine—an inhibitor of polyamine synthesis. J. Clin. Oncol., 2: 124–130, 1984.
74. Luk, G. Clinical and biologic studies of DFMO in the colon. In: L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 515–530. Boca Raton: CRC Press, 1992.
75. Love, R. R., Carbone, P. P., Verma, A. K., Gilmore, D., Carey, P., Tutsch, K. D., Pomplun, M., and Wilding, G. Randomized Phase I chemoprevention dose-seeking study of α-difluoromethylornithine. J. Natl. Cancer Inst., 85: 732–737, 1993.
76. Jaffe, B. M. Prostaglandins and cancer: an update. Prostaglandins, 6: 453–461, 1974.
77. Karmali, R. A. Prostaglandins and cancer. Prostaglandins Med., 5: 11–28, 1980.
78. Lombardino, J. G., and Wiseman, E. H. Piroxicam and other antiinflammatory oxicams. Med. Res. Rev., 2: 127–152, 1982.
79. Thun, M. J., Namboodiri, M. M., and Heath, C. W., Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593–1596, 1991
80. Zenser, T. V., and Davis, B. B. Arachidonic acid metabolism. In: V. E. Steele, C. W. Boone, G. D. Stoner, and G. J. Kelloff (eds.), Cellular and Molecular Targets for Chemoprevention, pp. 223–243. Boca Raton: CRC Press, 1992.
81. Plescia, O. J., Smith, A. H., and Grinwich, K. Subversion of immune system by tumor cells and the role of prostaglandins. Proc. Natl. Acad. Sci. USA, 75: 1848–1851, 1975.
82. Goodwin, J. S. Immunologic effects of nonsteroidal anti-inflammatory drugs. Am. J. Med., 77: 7–15, 1984.
83. Cohen, S. M., Zenser, T. V., Murasaki, G., Fukushima, S., Mattammal, M. F., Rapp, N. S., and Davis, B. B. Aspirin inhibition of N-[4-(5-nitro-2-furyl)-thiazolyl]formamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase. Cancer Res., 41: 3355–3359, 1981.
84. Wild, D., and Degan, G. H. Prostaglandin H synthetase-dependent mutagenic activity of heterocyclic aromatic amines of the IQ type. Carcinogenesis (Lond.), 8: 541–545, 1987.
85. Kudo, T., Narisawa, T., and Abo, S. Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann, 77: 260–264, 1980.
86. Narisawa, T., Sato, M., Tani, M., Kudo, T., Takahashi, T., and Goto, A. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res., 41: 1954–1957, 1981.
87. Pollard, M., and Luckert, P. H. Treatment of chemically-induced intestinal cancers with indomethacin. Proc. Soc. Exp. Biol. Med., 767: 161–164, 1981.
88. Pollard, M., and Luckert, P. H. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science (Washington DC), 274: 558–559, 1981.
89. Narisawa, T., Satoh, M., Sano, M., and Takahashi, T. Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis (Lond.), 4: 1225–1227, 1983.
90. Pollard, M., Luckert, P. H., and Schmidt, M. A. The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett., 27: 57–61, 1983.
91. Pollard, M., and Luckert, P. H. Effect of piroxicam on primary intestinal tumors induced in rats by N-methy I nitrosourea. Cancer Lett., 25: 117–121, 1984.
92. Metzger, U., Meier, J., Uhlschmid, M. D., and Weihe, H. Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis. Colon Rectum, 27: 366–369, 1984.
93. Birkenfeld, S., Zaltsman, Y. A., Krispin, M., Zakut, H., Zor, U., and Kohen, F. Antitumor effects of inhibitors of arachidonic acid cascade on experimentally-induced intestinal tumors. Dis. Colon Rectum, 30: 43–46, 1987.
94. Reddy, B., Maruyama, H., and Kelloff, G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a non-steroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res., 47: 5340–5346, 1987.
95. Moorghen, M., Ince, P., Finney, K. J., Sunter, J. P., Appleton, D. R., and Watson, A. J. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J. Pathol., 756: 341–347, 1988.
96. Murasaki, G., Zenser, T. V., Davis, B. B., and Cohen, S. M. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolylJformamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis. Carcinogenesis (Lond.), 5: 53–55, 1984.
97. Sakata, T., Hasegawa, R., Johansson, S. L., Zenser, T. V., and Cohen, S. M. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. Cancer Res., 46: 3903–3906, 1986.
98. Cornwall, H., Odukoya, O., and Shklar, G. Oral mucosal tumor inhibition by ibuprofen. J. Oral Maxillofac. Surg., 47: 795–800, 1983.
99. Perkins, T. M., and Shklar, G. Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin. Oral Surg. Oral Med. Oral Pathol., 53: 170–178, 1982.
100. Carter, C. A., Milholland, R. J., Shea, W., and Ip, M. M. Effect of the prostaglandin synthetase inhibitor indomethacin on 7, 12-dimethyl- benzlajanthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res., 43: 3559–3562, 1983.
101. McCormick, D., Madigan, M., and Moon, R. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res., 45: 1803–1806, 1985.
102. McCormick, D. L., and Wilson, A. M. Combination chemoprevention of rat mammary carcinogenesis by indomethacin and butylated hydroxytoluene. Cancer Res., 46: 3907–3911, 1986.
103. Noguchi, M., Taniya, T., Koyasaki, N., Kumaki, T., Miyazaki, I., and Mizukami, Y. Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7, 12-dimethylbenz(a)anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high-or low-fat diet. Cancer Res., 57: 2683–2689, 1991.
104. Viaje, A., Slaga, T. J., Wigler, M., and Weinstein, I. B. Effects of antiinflammatory agents on mouse skin tumor promotion, epidermal DNA synthesis, phorbol ester-induced cellular proliferation, and production of plasminogen activator. Cancer Res., 37: 1530–1536, 1977.
105. Fischer, S. M., Furstenberger, G., Marks, F., and Slaga, T. J. Events associated with mouse skin tumor promotion with respect to arachidonate acid metabolism: a comparison between SENCAR and NMRI mice. Cancer Res., 47: 3174–3179, 1987.
106. Fuerstenberger, G., Gross, M., and Marks, F. Eicosanoids and multistage carcinogenesis in NMRI mouse skin: role of prostaglandins E and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion). Carcinogenesis (Lond.), 70: 91–96, 1989.
107. Lowe, N. J., Connor, M. J., Breeding, J., and Chalet, M. Inhibition of ultraviolet-B epidermal ornithine decarboxylase induction and skin carcinogenesis in hairless mice by topical indomethacin and triamcinolone ace-tonide. Cancer Res., 42: 3941–3943, 1982.
108. Ambrus, J. L., Ambrus, C. M., Pickren, J. W., and Klein, E. Effect of sodium meclofenamate on ultraviolet radiation induced carcinogenesis. J. Med., 75: 161–168, 1984.
109. Rubio, C. A. Antitumoral activity of indomethacin on experimental esophageal tumors. J. Natl. Cancer Inst., 72: 705–707, 1984.
110. Takahashi, M., Furukawa, F., Toyoda, K., Sato, H., Hasegawa, R., Imaida, K., and Hayashi, Y. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis (Lond.), 11: 393–395, 1990.
111. Ramesha Rao, A., and Hussain, S. P. Modulation of methylcholanthrene-induced carcinogenesis in the uterine cervix of mouse by indomethacin. Cancer Lett., 43: 15–19, 1988.
112. Waddell, W. R., Ganser, G. F., Cerise, E. J., and Loughry, R. W. Sulindac for polyposis of the colon. Am. J. Surg., 757: 175–179, 1989.
113. Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M., and Attali, P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 707: 635–639, 1991.
114. Wattenberg, L. W., and Bueding, E. Inhibitory effects of 5-(2-pyrazinyl)-methyl-1, 2-dithiol-3-thione (oltipraz) on carcinogenesis induced by benzo(a)pyrene, diethylnitrosamine, and uracil mustard. Carcinogenesis (Lond.), 7: 1379–1381, 1986.
115. Roebuck, B. D., Liu, Y-L., Rogers, A. E., Groopman, J. D., and Kensler, T. W. Protection against aflatoxin Bi-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1, 2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res., 57: 5501–5506, 1991.
116. Kensler, T. W., Groopman, J. D., and Roebuck, B. D. Chemoprotection by oltipraz and other dithiolethiones. In: L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 205–226. Boca Raton: CRC Press, 1992.
117. Rao, C. V., Tokomo, K., Kelloff, G., and Reddy, B. S. Inhibition by dietary oltipraz of experimental intestinal carcinogenesis induced by azoxymethane in male F344 rats. Carcinogenesis (Lond.), 72: 1051–1055, 1991.
118. Ansher, S. S., Dolan, P., and Bueding, E. Chemoprotective effects of two dithiolthiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity. Hepatology, 3: 932–935, 1983.
119. Kensler, T. W., Egner, P. A., Trush, M. A., Bueding, E., and Groopman, J. D. Modification of aflatoxin Bi binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin, and a dithiolthione. Carcinogenesis (Lond.), 6: 759–763, 1985.
120. Kensler, T. W., Egner, P. A., Trush, M. A., Bueding, E., Groopman, J. D., and Roebuck, B. D. Mechanisms of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1, 2-dithiol-3-thione (oltipraz) and related 1, 2-dithiol-3-thiones and 1, 2-dithiol-3-ones. Cancer Res., 47: 4271–4277, 1987.
121. Moldeus, P., Cotgreave, I. A., and Berggren, M. Lung protection by a thiole containing antioxidant: N-acetyIcysteine. Respiration, 50: 31–42, 1986.
122. Liu, Y-L., Roebuck, B. D., Yager, J. D., Groopman, J. D., and Kensler, T. W. Protection by 5-(2-pyrazinyl)-4-methyl-1, 2-dithiol-3-thione (oltipraz) against the hepatotoxicity of aflatoxin Bi in the rat. Toxicol. Appl. Pharmacol., 93: 442–451, 1988.
123. Rao, C. V., Rivenson, A., Katiwalla, M., Kelloff, G. J., and Reddy, B. S. Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res., 53: 2502–2506, 1993.
124. LeRoy, J-P., Barreau, M., Cotrel, C., jeanmart, C., Messer, M., and Benazet, F. Laboratory studies of 35 972 R.P., a new schistosomicidal compound. Current Chemotherapy, Proceedings of the 10th International Congress of Chemotherapy, 7: 148–150, 1978.
125. Bella, H., Rahim, A. G. A., Mustafa, M. D., Ahmed, M. A. M., Wasfi, F. and Bennett, J. L. Oltipraz-antischistosomal efficacy in Sudanese infected with Schistosomal mansoni. Am. Trp. Med. Hyg., 31: 775–778, 1982.
126. Katz, N., Rocha, R. S., and Chaves, A. Assessment of oltipraz in Schistosoma mansoni. Rev. Inst. Med. Trop. Sao Paulo, 26: 147–151, 1984.
127. Sturrock, R. F. Oltipraz withdrawn from clinical trials. Trans. R. Soc. Trop. Med. Hygiene, 81: 528, 1987.
128. Benson, A. B., Mobarhan, S., Ratain, M., Sheehan, T., Berezin, F., Giovannozzi-Bannon, S., Ford, C., Rademaker, A. Phase I study of 4-methyl-5-(2-pyrazinyl)-1, 2-dithione-3-thiol (oltipraz, RP 35972) in male patients (pts) with previously resected colon polyps and first degree relatives of breast cancer patients. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 11: 144, 1992.
129. De Flora, S., Astengo, M., Serra, D., and Benicelli, C. Inhibition of urethane-induced lung tumors in mice by dietary N-acetylcysteine. Cancer Lett., 32: 235–241, 1986.
130. Wilpart, M., Speder, A., and Roberfroid, M. Anti-initiation activity of N-acetylcysteine in experimental colonic carcinogenesis. Cancer Lett., 31: 319–324, 1986.
131. De Flora, S., Rossi, G. A., and De Flora, A. Metabolic, desmutagenic, and anticarcinogenic effects of N-acetylcysteine. Respiration, 50: 43–49, 1986.
132. Bonanomi, L., and Gazzaniga, A. Toxicological, pharmacokinetic, and metabolic studies on acetylcysteine. Eur. J. Resp. Dis., 67: 45–51, 1980.
133. Reynolds, J. E. F., and Prasad, A. B. (eds.), Martindale. The Extra Pharmacopoeia, Ed. 28, pp. 77–78, 494, 691–692, 1673. London: The Pharmaceutical Press, 1982.
134. Nishino, H. Antitumor-promoting activity of glycyrrhetinic acid and its related compounds. In: L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 457–467. Boca Raton: CRC Press, 1992.
135. Wang, Z. Y., Agarwal, R., Zhou, Z. C., Bickers, D. R., and Mukhtar, H. Inhibition of mutagenicity in Salmonella typhimurium and skin tumor initiating and tumor promoting activities in SENCAR mice by glycyrrhetinic acid: comparison of 18α- and 18β-stereoisomers. Carcinogenesis (Lond.), 72: 187–192, 1991.
136. Henry, D. A., and Langmann, M. J. S. Adverse effects of anti-ulcer drugs. Drugs, 27: 444–459, 1981.
137. You, W-C., Blot, W. J., Chang, Y-S., Ershow, A., Yang, Z. T., An, Q., Henderson, B. E., Fraumeni, J. F., and Wang, T-G. Allium vegetables and reduced risk of stomach cancer. J. Natl. Cancer Inst., 81: 162–164, 1989.
138. Wargovich, M. J. Inhibition of gastrointestinal cancer by organosulfur compounds in garlic. In: L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 195–203. Boca Raton: CRC Press, 1992.
139. Buiatti, E., Palli, D., Decarli, A., Amadori, D., Avellini, C., Bianchi, S., Biserni, R., Cipriani, F., Cocco, P., Giacosa, A., Marubini, E., Puntoni, R., Vindigni, C., Fraumeni, J. Jr., and Blot, W. A case-control study of gastric cancer and diet in Italy. Int. J. Cancer, 44: 611–616, 1989.
140. Belman, S. Onion and garlic oils inhibit tumor promotion. Carcinogenesis (Lond.), 4: 1063–1065, 1983.
141. Hussain, S. P., Jannu, L. N., and Rao, A. R. Chemopreventive action of garlic on methylcholanthrene-induced carcinogenesis in the uterine cervix of mice. Cancer Lett., 49: 175–180, 1990.
142. Wargovich, M. J. Diallyl sulfide, a flavor component of garlic (Allium sativum), inhibits dimethylhydrazine-induced colon cancer. Carcinogenesis (Lond.), 8: 487–489, 1987.
143. Sparnins, V. L., Barany, G., and Wattenberg, L. W. Effects of organosulfur compounds from garlic and onions on benzolalpyrene-induced neoplasia and glutathione S-transferase activity in the mouse. Carcinogenesis (Lond.), 9: 131–134, 1988.
144. Wattenberg, L. W., Sparnins, V. L., and Barany, G. Inhibition of N-nitrosodiethylamine carcinogenesis in mice by naturally occurring organosulfur compounds and monoterpenes. Cancer Res., 49: 2689–2692, 1989.
145. Athar, M., Raza, H., Bickers, D. R., and Mukhtar, H. Inhibition of benzoyl peroxide-mediated tumor promotion in 7, 12-dimethylbenz(a)-anthracene-initiated skin of SENCAR mice by antioxidants nordihy-droguaiaretic acid and diallyl sulfide. J. Invest. Dermatol., 94: 162–165, 1990.
146. Wargovich, M. J., Woods, C., Eng, V. W. S., Stephens, L. C., and Gray, K. Chemoprevention of N-nitrosomethylbenzylamine-induced esophageal cancer in rats by the naturally occurring thioether, diallyl sulfide. Cancer Res., 48: 6872–6875, 1988.
147. Hu, P-J., and Wargovich, M. J. Effect of diallyl sulfide on MNNG- induced nuclear aberrations and ornithine decarboxylase activity in the glandular stomach mucosa of the Wistar rat. Cancer Lett., 47: 153–158, 1989.
148. Sumiyoshi, H., and Wargovich, M. J. Chemoprevention of 1, 2-dimethylhydrazine-induced colon cancer in mice by naturally occurring organosulfur compounds. Cancer Res., 50: 5084–5087, 1990.
149. Brady, J. F., Li, D., Ishizaki, H., and Yang, C. S. Effect of diallyl sulfide on rat liver microsomal nitrosamine metabolism and other monooxygenase activities. Cancer Res., 48: 5937–5940, 1988.
150. Wattenberg, L. W. Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothiocyanate and related compounds. J. Natl. Cancer Inst., 58: 395–398, 1977.
151. Wattenberg, L. W. Inhibition of carcinogen-induced neoplasia by sodium cyanate, tert-butyl isocyanate, and benzyl isothiocyanate administered subsequent to carcinogen exposure. Cancer Res., 47: 2991–2994, 1981
152. Wattenberg, L. W. Inhibitory effects of benzyl isothiocyanate administered shortly before diethyl nitrosamine or benzo[a]pyrene on pulmonary and forestomach neoplasia in A/J mice. Carcinogenesis (Lond.), 8: 1971–1973, 1987.
153. Morse, M. A., Wang, C-X., Stoner, G. D., Mandal, S., Conran, P. B., Amin, S. G., Hecht, S. S., and Chung, F-L. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1 -butanone-induced DNA adduct formation and tumorigenicity in the lung of F344 rat by dietary phenethyl isothiocyanate. Cancer Res., 49: 549–553, 1989.
154. Morse, M. A., Eklind, K. I., Hecht, S. S., Jordan, K. G., Choi, C., Desai, D. H., Amin, S. G., and Chung, F-L. Structure-activity relationships for inhibition of 4-(methylnitrosamino)-1 -(3-pyridyl)-1 -butanone lung tumorigenesis by arylalkyl isothiocyanates in A/J mice. Cancer Res., 57: 1846–1850, 1991.
155. Henderson, B. E., Ross, R. K., Shibata, A., Paganini-Hill, A., and Yu, M. C. Environmental carcinogens and anticarcinogens. In: L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 3–18. Boca Raton: CRC Press, 1992.
156. Chung, F., Morse, M. A., and Eklind, K. I. New potential chemopreventive agents for lung carcinogenesis of tobacco-specific nitrosamine. Cancer Res. (Suppl.), 52: 2719s–2722s, 1992.
157. Chung, F-L. Chemoprevention of lung carcinogenesis by aromatic isothiocyanates. In: L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 227–245. Boca Raton: CRC Press, 1992.
158. Stoner, G. D., Morrissey, D. T., Heur, Y-H., Daniel, E. M., Galati, A. J., and Wagner, S. A. Inhibitory effects of phenethyl isothiocyanate on N-nitrosobenzylmethylamine carcinogenesis in the rat esophagus. Cancer Res., 57: 2063–2068, 1991.
159. Takayasu, J., Nishino, H., and Iwashima, A. Antitumor-promoting activity of curcumin. Proc. Annu. Meet. Jpn. Cancer Assoc., 46: 60, 1987.
160. Huang, M-T., Smart, R. C., Wong, C-Q., and Conney, A. H. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol- 13-acetate. Cancer Res., 48: 5941–5946, 1988.
161. Soudamini, K. K., and Kuttan, R. Inhibition of chemical carcinogenesis by curcumin. J. Ethnopharmacol., 27: 227–233, 1989.
162. Huang, M-T., Lysz, T., Ferraro, T., and Conney, A. H. Inhibitory effects of curcumin on tumor promotion and arachidonic acid metabolism in mouse epidermis. In: L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 375–391 Boca Raton: CRC Press, 1992.
163. Srimal, R. C., and Dhawan, B. N. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J. Pharm. Pharmacol., 25: 447–452, 1973.
164. Rao, T. S., Basu, N., and Siddiqui, H. H. Antiinflammatory activity of curcumin analogues. Indian J. Med. Res., 75: 574–578, 1982.
165. Mukhopadhyay, A., Basu, N., Ghatak, N., and Gujral, P. K. Antiinflammatory and irritant activities of curcumin analogues in rats. Agents Actions, 72: 508–515, 1988.
166. Huang, M-T., Lysz, T., Ferraro, T., Abidi, T. F., Laskin, J. D., and Conney, A. H. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxy- genase activities in mouse epidermis. Cancer Res., 57: 813–819, 1991.
167. Sharma, O. P. Antioxidant activity of curcumin and related compounds. Biochem. Pharmacol., 25: 1811–1812, 1976.
168. Toda, S., Miyase, T., Arichi, H., Tanizawa, H., and Takino, Y. Natural antioxidants. III. Antioxidative components isolated from rhizome of Curcuma longa L. Chem. Pharm. Bull., 33: 1725–1728, 1985.
169. Srivastava, R. Inhibition of neutrophil response by curcumin. Agents Actions, 28: 298–303, 1989.
170. Nagabhushan, M., and Bhide, S. V. Nonmutagenicity of curcumin and its antimutagenic action versus chili and capsaicin. Nutr. Cancer, 8: 201–210, 1986.
171. Nagabhushan, M., Amonkar, A. J., and Bhide, S. V. In vitro antimutagenicity of curcumin against environmental mutagens. Food Chem. Toxicol., 25: 545–547, 1987.
172. British Industrial Biological Research Association. Turmeric and Curcumin. 1991.
173. Gupta, B., Kulshrestha, V. K., Srivastava, R. K., and Prasad, D. N. Mechanisms of curcumin induced gastric ulcer in rats. Indian J. Med. Res., 77: 806–814, 1980.
174. Kada, T., Kaneko, K., Matsuzaki, S., Matsuzaki, T., and Hara, Y. Detection and chemical identification of natural bio-antimutagens. A case of the green tea factor. Mutat. Res., 150:127–132, 1985.
175. Das, M., Khan, W. A., Asokan, P., Bickers, D. R., and Mukhtar, H. Inhibition of polycyclic aromatic hydrocarbon-DNA adduct formation in epidermis and lungs of SENCAR mice by naturally occurring plant phenols. Cancer Res., 47: 767–773, 1987.
176. Khan, W. A., Wang, Z. Y., Athar, M., Bickers, D. R., and Mukhtar, H. Inhibition of the skin tumorigenicity of (+/-)-7β, 8α-dihydroxy-9α, 10α- epoxy-7, 8, 9, 10-tetrahydrobenzo[a]pyrene by tannic acid, green tea polyphenols and quercetin in SENCAR mice. Cancer Lett., 42: 7–12, 1988.
177. Mukhtar, H., Das, M., Khan, W. A., Wang, Z. Y., Bik, D. P., and Bickers, D. R. Exceptional activity of tannic acid among naturally occurring plant phenols in protecting against 7, 12-dimethylbenz(a)anthracene-, benzo(a)pyrene-, 3-methylcholanthrene-, and N-methyl-N-nitrosourea-induced skin tumorigenesis in mice. Cancer Res., 48: 2361–2365, 1988.
178. Fujita, Y., Yamane, T., Tanaka, M., Kuwata, K., Okuzumi, J., Takahashi, T., Fujiki, H., and Okuda, T. Inhibitory effect of (-)epigallocatechin gallate on carcinogenesis with N-ethyl-N’-nitro-N-nitrosoguanidine in mouse duodenum. Jpn. J. Cancer Res., 80: 503–505, 1989.
179. Wang, Z. Y., Cheng, S. J., Zhou, Z. C., Athar, M., Khan, W. A., Bickers, D. R., and Mukhtar, H. Antimutagenic activity of green tea polyphenols. Mutat. Res., 223: 273–285, 1989.
180. Wang, Z. Y., Khan, W. A., Bickers, D. R., and Mukhtar, H. Protection against polycyclic aromatic hydrocarbon-induced skin tumor initiation in mice by green tea polyphenols. Carcinogenesis (Lond.), 70: 411–415, 1989.
181. Wang, Z. Y., Agarwal, R., Bickers, D. R., and Mukhtar, H. Protection against ultraviolet B radiation-induced photocarcinogenesis in hairless mice by green tea polyphenols. Carcinogenesis (Lond.), 12: 1527–1530, 1991.
182. Dixit, R., Teel, R. W., Daniel, F. B., and Stoner, G. D. Inhibition of benzo(a)pyrene and benzo(a)pyrene-trans-7, 8-diol metabolism and DNA binding in mouse lung explants by ellagic acid. Cancer Res., 45: 2951–2956, 1985.
183. Wood, A. W., Huang, M. T., Chang, R. L., Newmark, H. L., Lehr, R. E., Yagi, H., Sayer, J. M., Jerina, D. M., and Conney, A. H. Inhibition of the mutagenicity of bay-region diol epoxides of polycyclic aromatic hydrocarbons by naturally occurring plant phenols: exceptional activity of ellagic acid. Proc. Natl. Acad. Sci. USA, 79: 5513–5517, 1982.
184. Lesca, P. Protective effects of ellagic acid and other plant phenols on benzo[a]pyrene-induced neoplasia in mice. Carcinogenesis (Lond.), 4: 1651–1653, 1983.
185. Mukhtar, H., Del Tito, B. J., Jr., Marcelo, C. L., Das, M., and Bickers, D. R. Ellagic acid: a potent naturally occurring inhibitor of benzo[a]pyrene metabolism and its subsequent glucuronidation, sulfation and covalent binding to DNA in cultured BALB/C mouse keratinocytes. Carcinogenesis (Lond.), 5: 1565–1571, 1984.
186. Mukhtar, H., Das, M., and Bickers, D. R. Inhibition of methylcholanthrene-induced skin tumorigenicity in BALB/c mice by chronic oral feeding of trace amounts of ellagic acid in drinking water. Cancer Res., 46: 2262–2265, 1986.
187. Chang, R. L., Huang, M-T., Wood, A. W., Wong, C-Q., Newmark, H. L., Yagi, H., Sayer, J. M., Jerina, D. M., and Conney, A. H. Effect of ellagic acid and hydroxylated flavonoids on the tumorigenicity of benzo[a]pyrene and (+/-)-7β, 8α-dihydroxy-9α, 10α-epoxy-7, 8, 9, 10-tetrahydrobenzo[a]pyrene on mouse skin and in the newborn mouse. Carcinogenesis (Lond.), 6: 1127–1133, 1985.
188. Fiala, E. S., Reddy, B. S., and Weisburger, J. H. Naturally occurring anticarcinogenic substances in foodstuffs. Annu. Rev. Nutr., 5: 295–321, 1985.
189. Daniel, E. M., and Stoner, G. D. The effects of ellagic acid and 13-cisretinoic acid on N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats. Cancer Lett., 56: 117–124, 1991.
190. Smart, R. C., Huang, M. T., Chang, R. L., Sayer, J. M., Jerina, D. M., and Conney, A. H. Disposition of the naturally occurring antimutagenic plant phenol, ellagic acid, and its synthetic derivatives, 3-Odecylellagic acid and 3, 3’-di-O-methylellagic acid in mice. Carcinogenesis (Lond.), 7: 1663–1667, 1986.
191. Dixit, R., Gold, Bji, K., and Itri, L. Inhibition of N-methyl-N-nitrosourea- induced mutagenicity and DNA methylation by ellagic acid. Proc. Natl. Acad. Sci. USA, 83: 8039–8043, 1986.
192. Teel, R. W., and Martin, R. M. Absorption, distribution, and elimination of ellagic acid in the mouse following oral administration by gavage. Proc. Am. Assoc. Cancer Res., 28: 144, 1987.
193. Teel, R. W. Distribution and metabolism of ellagic acid in the mouse following intraperitoneal administration. Cancer Lett., 34: 165–171, 1987.
194. Girolami, A., and Cliffton, E. E. Hypercoagulable state induced in humans by the intravenous administration of purified ellagic acid. Thromb. Haemost., 77: 165–175, 1977.
195. Reynolds, J. E. F., and Prasad, A. B. (eds.), Martindale: The Extra Pharmacopoeia, Ed. 28, p. 785. London: The Pharmaceutical Press, 1982.
196. Spencer, S. R., Wilczak, C. A., and Talalay, P. Induction of glutathione transferases and NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues. Cancer Res., 50: 7871–7875, 1990.
197. Kuroda, K., Akao, M., Kanisawa, M., and Miyaki, K. Inhibitory effect of Capsella bursa-pastoris extract on growth of Ehrlich solid tumor in mice. Cancer Res., 36: 1900–1903, 1976.
198. Kuroda, K., and Akao, M. Inhibitory effect of fumaric acid and dicarboxylic acids on gastric ulceration in rats. Arch. Int. Pharmacodyn. Ther., 226: 324–330, 1977.
199. Kuroda, K., and Akao, M. Fumaric acid enhances DNA synthesis of rat hepatocytes by counteracting the toxicities of mitomycin C and aflatoxin B1. Jpn. J. Cancer Res., 77: 750–758, 1986.
200. Kuroda, K., Kanisawa, M., and Akao, M. Inhibitory effect of fumaric acid on forestomach and lung carcinogenesis by a 5-nitrofuran naphthyridine derivative in mice. J. Natl. Cancer Inst., 69: 1317–1320, 1982.
201. Kuroda, K., Terao, K., and Akao, M. Inhibitory effect of fumaric acid on methyl-4’-(dimethylamino)azobenzene-induced hepatocarcinogenesis in rats. J. Natl. Cancer Inst., 77: 855–857, 1983.
202. Kuroda, K., Terao, K., and Akao, M. Inhibitory effect of fumaric acid on hepatocarcinogenesis by thioacetamide in rats. J. Natl. Cancer Inst., 79: 1047–1105, 1987.
203. Levey, S., Lasichak, A. G., Brimi, R., Orten, J. M., Smyth, C. J., and Smith, A. H. A study to determine the toxicity of fumaric acid. J. Am. Pharm. Assoc., 35: 298–304, 1946.
204. Fitzhugh, O. G., and Nelson, A. A. The comparative chronic toxicities of fumaric, tartaric, oxalic, and maleic acids. J. Am. Pharm. Assoc., 36: 217–219, 1947.
205. Nieboer, C., de Hoop, D., van Loenen, A. C., Langendijk, P. N., and van Dijk, E. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J. Am. Acad. Dermatol., 20: 601–608, 1989.
206. Schwartz, A. G. Inhibition of spontaneous breast cancer formation in female C3H Avy/a mice by long-term treatment with dehydroepiandrosterone. Cancer Res., 39: 1129–1132, 1979.
207. Schwartz, A. G., and Tannen, R. H. Inhibition of 7, 12-dimethylbenz[a]anthracene- and urethan-induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandrosterone. Carcinogenesis (Lond.), 2: 1335–1337, 1981.
208. Schwartz, S. G., Hard, G. C., Pashko, L. L., Abou-Gharbia, M., and Swern, D. Dehydroepiandrosterone: an anti-obesity and anti-carcinogenic agent. Nutr. Cancer, 3: 46–53, 1981.
209. Nyce, J. W., Magee, P. N., Hard, G. C., and Schwartz, A. G. Inhibition of 1, 2-dimethylhydrazine-induced colon tumorigenesis in BALB/c mice by dehydroepiandrosterone. Carcinogenesis (Lond.), 5: 57–62, 1984.
210. Pashko, L. L., Rovito, R. J., Williams, J. R., Sobel, E. L., and Schwartz, A. G. Dehydroepiandrosterone (DHEA) and 3β-methylandrost-5-en-17-one: inhibitors of 7, 12-dimethylbenz|alanthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted skin papilloma formation in mice. Carcinogenesis (Lond.), 5: 463–466, 1984.
211. Pashko, L. L., Hard, G. C., Rovito, R. J., Williams, J. R., Sobel, E. L., and Schwartz, A. G. Inhibition of 7, 12-dimethylbenz(a)anthracene-induced skin papillomas and carcinomas by dehydroepiandrosterone and 3-β-methylandrost-5-en-17-one in mice. Cancer Res., 45: 164–166, 1985.
212. Moore, M. A., Thamavit, W., Tsuda, H., Sato, K., Ichihara, A., and Ito, N. Modifying influence of dehydroepiandrosterone on the development of dihydroxy-di-n-propyl-nitrosamine-initiated lesions in the thyroid, lung and liver of F344 rats. Carcinogenesis (Lond.), 7: 311–316, 1986.
213. Gordon, G. B., Ahantz, L. M., and Talalay, P. Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone. Adv. Enzyme Regul., 26: 355–382, 1987.
214. Weber, E., Moore, M. A., and Bannasch, P. Phenotypic modulation of hepatocarcinogenesis and reduction in N-nitrosomorpholine-induced hemangiosarcoma and adrenal lesion development in Sprague-Dawley rats by dehydroepiandrosterone. Carcinogenesis (Lond.), 9: 1191–1195, 1988.
215. Ratko, T. A., Detrisac, C. J., Mehta, R. G., Kelloff, G. J., and Moon, R. C. Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone. Cancer Res., 57: 481–486, 1991.
216. Schwartz, A. G., Lewbart, M. L., and Pashko, L. L. Inhibition of tumorigenesis by dehydroepiandrosterone and structural analogs. In: L. Wattenberg, M. Lipkin, C. W. Boone, and G. J. Kelloff (eds.), Cancer Chemoprevention, pp. 205–226. Boca Raton: CRC Press, 1992.
217. Schwartz, A. G., and Perantoni, A. Protective effect of dehydroepiandrosterone against aflatoxin B1- and 7, 12-dimethylbenz(a)anthracene- induced cytotoxicity and transformation in cultured cells. Cancer Res., 35: 2482–2487, 1975.
218. Feo, F., Pirisi, L., Pascale, R., Daino, L., Frassetto, S., Garcea, R., and Gaspa, L. Modulatory effect of glucose-6-phosphate dehydrogenase deficiency on benzo(a)pyrene toxicity and transforming activity for in vitro- cultured human skin fibroblasts. Cancer Res., 44: 3419–3425, 1984.
219. Feo, F., Ruggiu, M. E., Lenzerini, L., Garcea, R., Daino, L., Frassetto, S., Addis, V., Gaspa, L., and Pascale, R. Benzo(a)pyrene metabolism by lymphocytes from normal individuals and individuals carrying the Mediterranean variant of glucose-6-phosphate dehydrogenase. Int. J. Cancer, 39: 560–564, 1987.
220. Schwartz, A. G., Fairman, D. K., Polansky, M., Lewbart, M. L., and Pashko, L. L. Inhibition of 7, 12-dimethylbenz(a)anthracene-initiated and 12-Otetradecanoylphorbol-13-acetate-promoted skin papilloma formation in mice by dehydroepiandrosterone and two synthetic analogs. Carcinogenesis (Lond.), 10: 1809–1813, 1989.
221. Pashko, L. L., Schwartz, A. G., Abou-Gharbia, M., and Swern, D. Inhibition of DNA synthesis in mouse epidermis and breast epithelium by dehydroepiandrosterone and related steroids. Carcinogenesis (Lond.), 2: 717–721, 1981.
222. Knudsen, J. F., and Mahesh, V. B. Initiation of precocious sexual maturation in the immature rat treated with dehydroepiandrosterone. Endocrinology, 97: 458–468, 1975.
223. Schwartz, A. G., Lewbart, M. L., and Pashko, L. L. Novel dehydroepiandrosterone analogues with enhanced biological activity and reduced side effects in mice and rats. Cancer Res., 48: 4817–4822, 1988.
224. Yamada, J., Sakuma, M., I bed a, T., Fukuda, K., and Suga, T. Characteristics of dehydroepiandrosterone as a peroxisome proliferator. Biochem. Biophys. Acta, 7092: 233–243, 1991.
225. Pashko, L. L., Lewbart, M. L., and Schwartz, A. G. Inhibition of 12-O-tetradecanoyl-phorbol-13-acetate-promoted skin tumor formation by 16a- fluoro-5-androsten-17-one and its reversal by deoxyribonucleosides. Carcinogenesis (Lond.), 72: 2189–2192, 1991.
226. Ratko, T. A., Detrisac, C. J., Mehta, R. G., Kelloff, G. J., and Moon, R. C. Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone. Cancer Res., 57: 481–486, 1991.